Advances in Epithelial-Mesenchymal Transition (EMT)

A topical collection in Cells (ISSN 2073-4409). This collection belongs to the section "Stem Cells".

Viewed by 4317

Editors


E-Mail Website
Collection Editor

E-Mail Website
Collection Editor

E-Mail Website
Collection Editor
Department of Innovative Technologies in Clinical Medicine & Dentistry, University “G. d’Annunzio” Chieti-Pescara, 66100 Chieti, Italy
Interests: regenerative medicine; stem cells; microfluidics; oral stem cells; restorative dentistry; osteoregeneration; biomaterials; epithelial–mesenchymal transition; extracellular vesicles; exosomes; liposomes
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

The epithelial–mesenchymal transition (EMT) is a process that leads to the transdifferentiation of epithelial cells into motile mesenchymal cells. This is an essential event in development, wound healing, and stem cell behaviour, and contributes pathologically to fibrosis and cancer progression.

The cell differentiation is regulated by several transcription factors and molecular mechanisms that still remain unknown. During EMT, cell–cell and cell–extracellular matrix interactions are remodelled, and a new transcriptional programme is activated to promote the modifications in cellular morphology and functions. We invite colleagues to contribute editorials, original research articles, or review papers with recent findings on the mechanisms and roles of EMT in normal and neoplastic tissues, during physiological and pathological processes.

Prof. Dr. Oriana Trubiani
Dr. Francesca Diomede
Dr. Jacopo Pizzicanella
Dr. Guya Marconi
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epithelial–mesenchymal transition
  • fibrosis
  • wound healing
  • cancer
  • development
  • stem cell behaviour
  • transcriptional factor
  • cell differentiation

Published Papers (2 papers)

2022

24 pages, 5845 KiB  
Article
Deciphering the Antifibrotic Property of Metformin
by Axelle Septembre-Malaterre, Chailas Boina, Audrey Douanier and Philippe Gasque
Cells 2022, 11(24), 4090; https://doi.org/10.3390/cells11244090 - 16 Dec 2022
Cited by 3 | Viewed by 1657
Abstract
Fibrosis is a chronic progressive and incurable disease leading to organ dysfunction. It is characterized by the accumulation of extracellular matrix proteins produced by mesenchymal stem cells (MSCs) differentiating into myofibroblasts. Given the complexity of its pathophysiology, the search for effective treatments for [...] Read more.
Fibrosis is a chronic progressive and incurable disease leading to organ dysfunction. It is characterized by the accumulation of extracellular matrix proteins produced by mesenchymal stem cells (MSCs) differentiating into myofibroblasts. Given the complexity of its pathophysiology, the search for effective treatments for fibrosis is of paramount importance. Metformin, a structural dimethyl analog of the galegine guanide extracted from the “French Lilac” (Fabaceae Galega officinalis), is the most widely used antidiabetic drug, recently recognized for its antifibrotic effects through ill-characterized mechanisms. The in vitro model of TGF-β1-induced fibrosis in human primary pulmonary mesenchymal stem cells (HPMSCs), identified as CD248+ and CD90+ cells, was used to study the effects of metformin extracts. These effects were tested on the expression of canonical MSC differentiation markers, immune/inflammatory factors and antioxidative stress molecules using qRT-PCR (mRNA, miRNA), immunofluorescence and ELISA experiments. Interestingly, metformin is able to reduce/modulate the expression of different actors involved in fibrosis. Indeed, TGF-β1 effects were markedly attenuated by metformin, as evidenced by reduced expression of three collagen types and Acta2 mRNAs. Furthermore, metformin attenuated the effects of TGF-β1 on the expression of PDGF, VEGF, erythropoietin, calcitonin and profibrotic miRs, possibly by controlling the expression of several key TGF/Smad factors. The expression of four major fibrogenic MMPs was also reduced by metformin treatment. In addition, metformin controlled MSC differentiation into lipofibroblasts and osteoblasts and had the ability to restore redox balance via the Nox4/Nrf2, AMP and Pi3K pathways. Overall, these results show that metformin is a candidate molecule for antifibrotic effect and/or aiming to combat the development of chronic inflammatory diseases worldwide. Full article
Show Figures

Graphical abstract

18 pages, 837 KiB  
Review
Potential Therapeutic Role of Mesenchymal-Derived Stem Cells as an Alternative Therapy to Combat COVID-19 through Cytokines Storm
by Tarun Kumar Upadhyay, Rashmi Trivedi, Fahad Khan, Pratibha Pandey, Amit Baran Sharangi, Harsh Goel, Mohd Saeed, Moon Nyeo Park and Bonglee Kim
Cells 2022, 11(17), 2686; https://doi.org/10.3390/cells11172686 - 29 Aug 2022
Cited by 3 | Viewed by 2048
Abstract
Medical health systems continue to be challenged due to newly emerging COVID-19, and there is an urgent need for alternative approaches for treatment. An increasing number of clinical observations indicate cytokine storms to be associated with COVID-19 severity and also to be a [...] Read more.
Medical health systems continue to be challenged due to newly emerging COVID-19, and there is an urgent need for alternative approaches for treatment. An increasing number of clinical observations indicate cytokine storms to be associated with COVID-19 severity and also to be a significant cause of death among COVID-19 patients. Cytokine storm involves the extensive proliferative and hyperactive activity of T and macrophage cells and the overproduction of pro-inflammatory cytokines. Stem cells are the type of cell having self-renewal properties and giving rise to differentiated cells. Currently, stem cell therapy is an exciting and promising therapeutic approach that can treat several diseases that were considered incurable in the past. It may be possible to develop novel methods to treat various diseases by identifying stem cells’ growth and differentiation factors. Treatment with mesenchymal stem cells (MSCs) in medicine is anticipated to be highly effective. The present review article is organized to put forward the positive arguments and implications in support of mesenchymal stem cell therapy as an alternative therapy to cytokine storms, to combat COVID-19. Using the immunomodulatory potential of the MSCs, it is possible to fight against COVID-19 and counterbalance the cytokine storm. Full article
Show Figures

Figure 1

Back to TopTop